Geode Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-107,778
| Closed | -$4.28M | – | 4470 |
|
|
2026
Q1 | $4.28M | Buy |
107,778
+20,168
| +23% | +$516K | ﹤0.01% | 2814 |
|
|
2025
Q4 | $2.19M | Sell |
87,610
-7,422
| -8% | -$188K | ﹤0.01% | 3134 |
|
|
2025
Q3 | $2.3M | Buy |
95,032
+7,597
| +9% | +$135K | ﹤0.01% | 3127 |
|
|
2025
Q2 | $1.15M | Buy |
87,435
+26,994
| +45% | +$342K | ﹤0.01% | 3283 |
|
|
2025
Q1 | $869K | Buy |
60,441
+3,184
| +6% | +$52.1K | ﹤0.01% | 3352 |
|
|
2024
Q4 | $959K | Buy |
57,257
+660
| +1% | +$10.9K | ﹤0.01% | 3397 |
|
|
2024
Q3 | $905K | Buy |
56,597
+23,058
| +69% | +$282K | ﹤0.01% | 3388 |
|
|
2024
Q2 | $303K | Hold |
33,539
| – | – | ﹤0.01% | 3762 |
|
|
2024
Q1 | $379K | Hold |
33,539
| – | – | ﹤0.01% | 3706 |
|
|
2023
Q4 | $267K | Buy |
33,539
+1,706
| +5% | +$11.4K | ﹤0.01% | 3842 |
|
|
2023
Q3 | $206K | Buy |
31,833
+6,713
| +27% | +$45.9K | ﹤0.01% | 3971 |
|
|
2023
Q2 | $155K | Buy |
25,120
+2,434
| +11% | +$11.5K | ﹤0.01% | 4155 |
|
|
2023
Q1 | $87.3K | Buy |
22,686
+9,258
| +69% | +$33.9K | ﹤0.01% | 4389 |
|
|
2022
Q4 | $41K | Hold |
13,428
| – | – | ﹤0.01% | 4642 |
|
|
2022
Q3 | $53K | Buy |
+13,428
| New | +$61.4K | ﹤0.01% | 4755 |
|
|
2021
Q3 | – | Sell |
-9,513
| Closed | -$211K | – | 4861 |
|
|
2021
Q2 | $211K | Buy |
+9,513
| New | +$224K | ﹤0.01% | 4323 |
|
Geode Capital Management's CNTA Position: Q2 2026 in Review
Geode Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 107,778 shares — an estimated $4.28M sold.
Geode Capital Management first reported a position in CNTA in Q2 2021 and held it in 16 quarters. The position peaked at $4.28M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Geode Capital Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Geode Capital Management sold 107,778 Centessa Pharmaceuticals shares in Q2 2026, an estimated $4.28M.
- Geode Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 16 quarters.
- Geode Capital Management's Centessa Pharmaceuticals position peaked at $4.28M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.